Accelerate global life science and gene-drug research and development by providing a full spectrum of gene delivery solutions.
VectorBuilder (Chinese: 云舟生物), a gene delivery enterprise, announced that it had completed a Series C financing round worth CNY 410 million. This funding round was led by Legend Capital (Chinese: 君联资本), Sui Kai Equity Investment (Chinese: 穗开投资) and Yuexiu Financial Holdings Industrial Fund (Chinese: 越秀产业基金), followed by C&D Emerging Industry Equity Investment (Chinese: 建发新兴投资), Wanlian Securities (Chinese: 万联证券), Guangzhou Industrial Investment and Capital Operation Holding Group (Chinese: 广州产投资本) and Jingtingshan Venture Capital (Chinese: 敬亭山创投).
VectorBuilder will continue to upgrade the gene delivery platform, expand production capacity, strengthen brand communication and market promotion and boost the research and development of global life sciences and gene medicines.
VectorBuilder offers custom vectors, CRO and CDMO services and IP out-licensing services. The company has more than 10 representative offices worldwide, and 90% of its income comes from overseas. It has provided more than 1.2 million gene delivery solutions to more than 4000 scientific research institutes and pharmaceutical companies worldwide.
Gene delivery is a key process in the development of gene drugs. However, current life science laboratories face low-efficiency, time-consuming and high-cost problems in vector construction. The company’s online intelligent drug carrier design platform ‘VectorBuilder,’ combined with the offline high-throughput production management platform, enables highly personalized vectors and viruses to be easy to scale up and cost-effective.
CRO, which focuses on drug carrier designs, also includes Ubrigene (Chinese: 宜明细胞), OBiO (Chinese: 和元生物)and PackGene Biotech (Chinese: 派真生物).